Golcadomide Clinical Trials (2026): 15 Studies for Refractory Primary Mediastinal Large B-Cell Lymphoma & Large B-cell Lymphoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
15 Golcadomide clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 14 indications (including Refractory Primary Mediastinal Large B-Cell Lymphoma & Large B-cell Lymphoma) and 1,852 total planned enrollment. 2 Phase 3 Golcadomide trials and 5 Phase 2 are listed. 10 Golcadomide clinical trials are actively recruiting at 26 U.S. sites across 16 states. Most recent activity: NCT06911502 (Jul 2030).
Where to Participate: All Golcadomide Trial Sites in the U.S. (26 sites across 16 states)
Every actively recruiting Golcadomidetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Infirmary Cancer Care | Mobile36607 | NCT06911502 | Map |
| AK | Alaska Oncology and Hematology | Anchorage99508 | NCT06911502 | Map |
| AZ | Mayo Clinic in Arizona | Scottsdale85259 | NCT06834373 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT06911502 | Map |
| CA | UCSF Helen Diller Medical Center at Parnassus Heights | San Francisco94143 | NCT06911502 | Map |
| CA | UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program | San Francisco94143 | NCT05169515 | Map |
| CO | University of Colorado | Aurora80045 | NCT05169515 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT06834373 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT05169515 | Map |
| GA | Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | Marietta30060 | NCT06911502 | Map |
| GA | Southeastern Regional Medical Center | Newnan30265 | NCT06911502 | Map |
| IL | The University of Chicago | Chicago60637 | NCT05169515 | Map |
| MD | Greater Baltimore Medical Center | Towson21204 | NCT06911502 | Map |
| MN | Mayo Clinic Health System in Albert Lea | Albert Lea56007 | NCT06834373 | Map |
| MN | Mayo Clinic Health Systems-Mankato | Mankato56001 | NCT06834373 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06834373 | Map |
| MS | Hattiesburg Clinic Hematology/Oncology | Hattiesburg39401-7233 | NCT06911502 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT05169515 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06209619 | Map |
| TX | Texas Oncology - Central/South Texas | Austin78705 | NCT06911502 | Map |
| TX | UT MD Anderson Cancer Center | Houston77030 | NCT05169515 | Map |
| TX | Texas Oncology - Northeast Texas | Tyler75702 | NCT06911502 | Map |
| VA | Hematology Oncology Associates of Fredericksburg | Fredericksburg22408 | NCT06911502 | Map |
| VA | Blue Ridge Cancer Care | Roanoke24014 | NCT06911502 | Map |
| WI | Mayo Clinic Health System-Eau Claire Clinic | Eau Claire54701 | NCT06834373 | Map |
| WI | Mayo Clinic Health System-Franciscan Healthcare | La Crosse54601 | NCT06834373 | Map |
Golcadomide clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | withdrawn | not yet recruiting | Total |
|---|---|---|---|---|---|---|
| P1 | 2 | 1 | 1 | 4 | ||
| P1/P2 | 1 | 1 | 2 | 4 | ||
| P2 | 3 | 2 | 5 | |||
| P3 | 1 | 1 | 2 |
Recruiting Golcadomide clinical trials (10)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06911502 | GOLSEEK-4A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) | P3 | Follicular Lymphoma | 400 | Jul 2025 |
| NCT06835530 | FIL_RICCOA Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) | P2 | Diffuse Large B Cell Non-Hodgkin Lymphoma | 47 | Apr 2025 |
| NCT07578077 | Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | P1/P2 | Recurrent Mantle Cell Lymphoma | 58 | Dec 2026 |
| NCT07018752 | PlaTformA Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas | P1/P2 | Peripheral T Cells Lymphoma (PTCL) | 49 | Aug 2025 |
| NCT07608731 | Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas | P1 | Large B-cell Lymphoma | 18 | Jun 2026 |
| NCT05169515 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | P1 | Non-Hodgkin Lymphoma | 121 | Oct 2022 |
| NCT06271057 | Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse | P2 | Diffuse Large B-cell Lymphoma Refractory | 65 | Jun 2024 |
| NCT07269639 | Go-Pro-DLBCLGolcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma | P1/P2 | Large B-Cell Lymphoma (LBCL) | 20 | Jan 2026 |
| NCT06834373 | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | P2 | Large B-Cell Lymphoma With IRF4 Rearrangement | 41 | Apr 2025 |
| NCT06209619 | CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma | P1 | B-Cell Non-Hodgkin Lymphoma-Recurrent | 18 | Jan 2024 |
Golcadomide clinical trials by indication
Large B-cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07608731 | — | P1 | not yet recruiting | Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas |
| NCT06356129 | GOLSEEK-1 | P3 | active not recruiting | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma |
Recurrent Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07578077 | — | P1/P2 | not yet recruiting | Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma |
Large B-Cell Lymphoma (LBCL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07269639 | Go-Pro-DLBCL | P1/P2 | not yet recruiting | Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma |
Peripheral T Cells Lymphoma (PTCL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07018752 | PlaTform | P1/P2 | recruiting | A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas |
Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06911502 | GOLSEEK-4 | P3 | recruiting | A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) |
Non Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06767956 | — | P1/P2 | withdrawn | Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy |
Diffuse Large B Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06835530 | FIL_RICCO | P2 | recruiting | A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) |
Large B-Cell Lymphoma With IRF4 Rearrangement (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06834373 | — | P2 | recruiting | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy |
Lymphoma, Follicular (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06425302 | GOLSEEK-2 | P2 | active not recruiting | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma |
Diffuse Large B-cell Lymphoma Refractory (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06271057 | — | P2 | recruiting | Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse |
Healthy Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06363630 | CYP | P1 | completed | A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants |
B-Cell Non-Hodgkin Lymphoma-Recurrent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06209619 | — | P1 | recruiting | CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma |
Follicular Lymphoma Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05788081 | TOP-FLOR | P2 | active not recruiting | Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. |
Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05169515 | — | P1 | recruiting | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma |
Golcadomide pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| GOLSEEK-4 | NCT06911502 | P3 | recruiting | Follicular Lymphoma | 400 | — |
| GOLSEEK-1 | NCT06356129 | P3 | active not recruiting | Large B-cell Lymphoma | 850 | — |
| FIL_RICCO | NCT06835530 | P2 | recruiting | Diffuse Large B Cell Non-Hodgkin Lymphoma | 47 | — |
| GOLSEEK-2 | NCT06425302 | P2 | active not recruiting | Lymphoma, Follicular | 90 | — |
| TOP-FLOR | NCT05788081 | P2 | active not recruiting | Follicular Lymphoma Stage II | 40 | — |
Terminated and withdrawn Golcadomide trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT06767956withdrawnGolcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
All Golcadomide trials (15)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06911502 | GOLSEEK-4 | A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) | P3 | recruiting | 400 | Celgene | Jul 2025 |
| NCT06835530 | FIL_RICCO | A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) | P2 | recruiting | 47 | Fondazione Italiana Linfomi - ETS | Apr 2025 |
| NCT07578077 | Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | P1/P2 | not yet recruiting | 58 | City of Hope Medical Center | Dec 2026 | |
| NCT07018752 | PlaTform | A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas | P1/P2 | recruiting | 49 | The Lymphoma Academic Research Organisation | Aug 2025 |
| NCT07608731 | Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas | P1 | not yet recruiting | 18 | Allison Winter | Jun 2026 | |
| NCT05169515 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | P1 | recruiting | 121 | Hoffmann-La Roche | Oct 2022 | |
| NCT06356129 | GOLSEEK-1 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | P3 | active not recruiting | 850 | Celgene | Jun 2024 |
| NCT06271057 | Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse | P2 | recruiting | 65 | The Lymphoma Academic Research Organisation | Jun 2024 | |
| NCT06425302 | GOLSEEK-2 | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma | P2 | active not recruiting | 90 | Celgene | Aug 2024 |
| NCT07269639 | Go-Pro-DLBCL | Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma | P1/P2 | not yet recruiting | 20 | Seoul National University Hospital | Jan 2026 |
| NCT06767956 | Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy | P1/P2 | withdrawn | 0 | University of Pittsburgh | Jun 2025 | |
| NCT05788081 | TOP-FLOR | Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. | P2 | active not recruiting | 40 | Olivia Newton-John Cancer Research Institute | Aug 2023 |
| NCT06834373 | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | P2 | recruiting | 41 | Mayo Clinic | Apr 2025 | |
| NCT06209619 | CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma | P1 | recruiting | 18 | Nathan Denlinger | Jan 2024 | |
| NCT06363630 | CYP | A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants | P1 | completed | 35 | Celgene | Apr 2024 |
Golcadomide clinical trials: frequently asked questions
- How many Golcadomide clinical trials are there?
- 15 Golcadomide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 7 are actively recruiting participants. 1 is marked completed.
- Are Golcadomide clinical trials recruiting in 2026?
- Yes — 7 Golcadomide trials are actively recruiting in 2026, with 26 U.S. sites across 16 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Golcadomide being studied for?
- Golcadomide is being studied for Refractory Primary Mediastinal Large B-Cell Lymphoma, Large B-cell Lymphoma, Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Refractory and 56 more. The trials are grouped by indication on this page.
- What phase is Golcadomide in?
- Golcadomide clinical trials span 2 Phase 3, 5 Phase 2, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Golcadomide clinical trials?
- The lead sponsor across the most Golcadomide trials is Celgene, with 10 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Golcadomideas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: